Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clodronic acid

Drug Profile

Clodronic acid

Alternative Names: 177501; Ascredar; Bonefos; Bonephos; CL-I.A.; Cl2MDP; Clasteon; Clastoban; Climaclod; Clodeosten; Clodron; Clodron beta; Clodronate; Clodronate disodium; Clody; Difosfonal; Dolkin; Hemocalcin; KCO 692; Lodronat; Loron; Lytos; Mebonat; Moticlod; Nikclod; Ossiten; Ostac; Osteonorm; Osteostab; Sindronat; ZK 00091106

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering Oy
  • Developer Abiogen Pharma; Bayer HealthCare Pharmaceuticals; Roche; Schering Oy
  • Class Antihypercalcaemics; Antirheumatics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Collagen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases; Malignant hypercalcaemia; Postmenopausal osteoporosis
  • Phase II Osteoarthritis

Most Recent Events

  • 03 Jun 2021 Abiogen Pharma completes a phase-II clinical trials in Osteoarthritis in Poland, Italy and Czech Republic (Intra-articular) (EudraCT2018-002081-39)
  • 14 Mar 2019 Phase-II clinical trials in Osteoarthritis in Poland (Intra-articular) (EudraCT2018-002081-39)
  • 14 Mar 2019 Phase-II clinical trials in Osteoarthritis in Czech Republic (Intra-articular) (EudraCT 2018-002081-39)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top